Molecular Diagnostics News and Research

RSS

Veredus Labs develops ‘Lab-on-Chip’ to detect and differentiate several food-borne pathogens, including Escherichia coli

Veredus Laboratories, a leading provider of molecular detection tests, and its technology partner, STMicroelectronics (NYSE: STM), today announced the successful development and deployment of VereFoodborne™, a Lab-on-Chip application that is able to detect 10 to 12 food-borne pathogens in one test, including the Shiga toxin-producing Escherichia coli (E. coli) responsible for the recent severe food poisoning outbreak in Europe.

23 Jun 2011

Veredus Lab-on-Chip application can diagnose and differentiate food-borne pathogens

Veredus Laboratories, a leading provider of molecular detection tests, and its technology partner, STMicroelectronics, today announced the successful development and deployment of VereFoodborne, a Lab-on-Chip application that is able to detect 10 to 12 food-borne pathogens in one test, including the Shiga toxin-producing Escherichia coli responsible for the recent severe food poisoning outbreak in Europe.

23 Jun 2011

Mayo Clinic announces collaboration on genotyping test for Warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, to clients throughout the world.

20 Jun 2011

GenMark prices public offering of common stock

GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing proprietary eSensor detection technology, announced today the pricing of a public offering of 7,065,600 shares of its common stock at a price to the public of $4.25 per share.

17 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

Merck, Roche partner to develop cancer diagnostic assays

Merck, known outside the United States and Canada as MSD, and Roche today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio.

From Roche Sequencing and Life Science 7 Jun 2011

New blog aims to help dispel many myths behind cervical smear test

In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected. A new blog, entitled, 'my diary from down under', aims to help dispel many of the myths surrounding having a smear with the aim of putting women at ease and encouraging more women to attend their cervical screens when invited.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

Additional data supporting utility of PAM50 gene signature for breast cancer to be presented at ASCO 2011

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.

4 Jun 2011

Nuvera announces results of blinded study on breast cancer assay for taxane chemotherapy response

Nuvera Biosciences, a molecular diagnostics company that develops gene-based diagnostic assays for personalized medicine in cancer, announced the results of a blinded validation study on its breast cancer assay for taxane chemotherapy response.

4 Jun 2011

Rheonix to receive U.S. patent for powerful microfluidic platform

Rheonix, Inc., developer of the Rheonix CARD system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems," and on April 13, 2011 it allowed Patent Application Number 11/594,444, "Microfluidic Systems," to the Company.

3 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

EPO awards Trilink patent for CleanAmp Primers

TriLink BioTechnologies, Inc., a leader in manufacturing high quality oligonucleotides and nucleoside triphosphates, announced today the award of their CleanAmp Primer patent by the European Patent Office (EPO Patent no. 2032714).

27 May 2011

OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer

A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone.

From Quest Diagnostics 27 May 2011

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Roche announced today that the cobas TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now commercially available in Europe.

23 May 2011

Lab21 acquires molecular diagnostics company Myconostica Ltd

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has today announced that it has acquired Myconostica Ltd, a molecular diagnostic company focussing on the diagnosis of fungal infections of clinical importance.

23 May 2011

Gen-Probe seeks FDA regulatory clearance for PANTHER fully automated and integrated molecular testing system

Gen-Probe Incorporated announced today that the Company has filed a 510(k) application with the US Food and Drug Administration for its PANTHER system, a fully automated and integrated molecular testing system designed with the flexibility to handle a wide range of testing needs.

20 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011